Keenova Therapeutics Director Katina Dorton Receives 4,406 RSUs

What Happened Katina Dorton, a director of Keenova Therapeutics plc, received a grant of 4,406 restricted stock units (RSUs) on July 15, 2026. The award is recorded at $0.00 per unit (no cash paid) and is a derivative grant that will settle into ordinary shares upon vesting.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (filing appears timely).
• Transaction type: Award/Grant (code A) — 4,406 RSUs @ $0.00.
• Settlement: Each RSU converts to one ordinary share upon vesting (Footnote F1).
• Vesting schedule: RSUs vest on the earlier of (i) the first anniversary of the grant or (ii) the issuer's next annual general meeting (Footnote F2).
• Shares owned after transaction: Not stated in the filing.
• Remarks: Filing notes it constitutes notice to the issuer under Part V of the Companies Act 2014.

Context RSUs are restricted awards that do not represent immediately tradable shares; they convert to ordinary shares only when they vest. This grant is typical compensation for directors and does not involve an open-market purchase or sale. The filing provides disclosure of the award but does not indicate any immediate cash flow or selling activity by the insider.